Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001209191-15-041823)

Filing Details

Accession Number:: 0001209191-15-041823
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-05-12 17:31:29
Reporting Period:: 2015-05-11

Filing Date:: 2015-05-12
Accepted Time:: 2015-05-12 17:31:29
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1348649	Colucid Pharmaceuticals Inc.	CLCD	Pharmaceutical Preparations (2834)	203419541

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1388325	A/S Novo	Tuborg Havnevej 19 Hellerup G7 2900		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-05-11	1,756,563	$0.00	1,756,563	No	4	C	Direct
Common Stock	Acquisiton	2015-05-11	1,300,000	$10.00	3,056,563	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	SERIES C PREFERRED STOCK	Disposition	2015-05-11	1,756,563	$0.00	1,756,563	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct

Footnotes

Gives effect to the 1-for-40.7 reverse stock split of the capital stock of the Issuer, which became effective on April 17, 2015. The Series C Preferred Stock had no expiration date and automatically converted into the Issuer's common stock for no additional consideration on a one for one basis upon the closing of the Issuer's initial public offering.
Represents a purchase from the underwriters in the Issuer's public offering.